Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

Investigator: Marion Peters, MD
Sponsor: Brigham and Women's Hospital

Location(s): United States


A5320 (also known as the V-HICS study) is an observational, prospective, long-term follow-up study for men and women who have hepatitis C virus (HCV) infection alone (mono-infected) or who have both HCV and HIV-1 infection (co-infected).  Persons who were treated with a direct-acting anti-viral (DAA) therapy as a component of their hepatitis C treatment regimen in a clinical trial are eligible.

This study will help to understand the impact of successful (sustained viral response, SVR) or unsuccessful HCV treatment on a person’s health over many years. It will also help us understand how long resistance to new hepatitis C medications lasts and whether it affects future hepatitis C treatments.  The study will look at each person’s HCV and genetic differences that might play a role in the success or failure of the HCV treatments. This study will also measure how treatment success or failure affects a person’s quality of life.